Common use

The active ingredient present in this medication is daclatasvir – 60 mg. Daclatasvir is a direct-acting antiviral (DAA) medication specifically developed for the treatment of chronic hepatitis C virus (HCV) infection. As an NS5A inhibitor, daclatasvir works by blocking the HCV nonstructural protein NS5A, which plays a critical role in viral RNA replication and assembly of new virus particles. Clinical research has demonstrated that daclatasvir targets two distinct steps in the viral replication process, enabling a rapid and significant decline in HCV RNA levels in the bloodstream. When you buy daclatasvir online, you receive a proven hepatitis C treatment that is indicated for use in combination with sofosbuvir, with or without ribavirin, for patients with chronic HCV genotype 1 or genotype 3 infections. This daclatasvir generic formulation offers the same pharmaceutical quality as branded versions at a more accessible price point. It is strongly advised to use effective contraception and avoid pregnancy during combination treatment with daclatasvir and sofosbuvir with ribavirin, continuing for at least 6 months after completion of the full treatment course.

Dosage and direction

The recommended dosage of daclatasvir is 60 mg, taken orally once daily with or without food. The tablet should be swallowed whole with water at approximately the same time each day to maintain consistent drug levels. Recommended treatment regimen and duration for daclatasvir are as follows:

Genotype 1:
Without cirrhosis – Daclatasvir + sofosbuvir for 12 weeks
Compensated (Child-Pugh A) cirrhosis – Daclatasvir + sofosbuvir for 12 weeks
Decompensated (Child-Pugh B or C) cirrhosis – Daclatasvir + sofosbuvir + ribavirin for 12 weeks
Post-liver transplant – Daclatasvir + sofosbuvir + ribavirin for 12 weeks

Genotype 3:
Without cirrhosis – Daclatasvir + sofosbuvir for 12 weeks
Compensated (Child-Pugh A) or decompensated (Child-Pugh B or C) cirrhosis – Daclatasvir + sofosbuvir + ribavirin for 12 weeks
Post-liver transplant – Daclatasvir + sofosbuvir + ribavirin for 12 weeks

For specific dosage recommendations for sofosbuvir and ribavirin, refer to their respective prescribing information. Do not modify your dose or stop treatment without consulting your hepatologist or treating physician, as incomplete treatment may lead to antiviral resistance.

Precautions

The concomitant use of daclatasvir with other medications may result in known or potentially significant drug interactions. Some interactions may lead to loss of therapeutic effect of daclatasvir and possible development of viral resistance, while others may require dosage adjustments of daclatasvir or concomitant medications, or may cause clinically significant adverse reactions from increased drug exposure. Postmarketing surveillance has identified cases of symptomatic bradycardia (dangerously slow heart rate) and cases requiring pacemaker intervention when amiodarone is coadministered with sofosbuvir in combination with another HCV direct-acting antiviral, including daclatasvir. A fatal cardiac arrest was reported in a patient receiving a sofosbuvir-containing regimen. Bradycardia generally resolved after discontinuation of HCV treatment, though the exact mechanism remains unknown. For patients currently taking amiodarone who have no alternative treatment options and will be coadministered daclatasvir and sofosbuvir, continuous cardiac monitoring in an inpatient setting is required for the first 48 hours. After this period, outpatient or self-monitoring of heart rate should continue on a daily basis through at least the first 2 weeks of antiviral treatment.

Contraindications

The following drugs are strictly contraindicated with daclatasvir due to the risk of significantly reduced antiviral efficacy:
Anticonvulsants – phenytoin, carbamazepine (strong CYP3A inducers)
Antimycobacterial agents – rifampin (rifampicin)
Herbal products – St. John’s wort (Hypericum perforatum)
These medications can dramatically reduce daclatasvir plasma concentrations, potentially leading to treatment failure and development of hepatitis C viral resistance.

Possible side effect

The most common side effects observed during clinical trials of daclatasvir in combination with sofosbuvir (with or without ribavirin), peginterferon alfa/ribavirin, asunaprevir, or asunaprevir/peginterferon alfa/ribavirin include: fatigue, headache, pruritus (itching), insomnia, influenza-like illness, dry skin, nausea, decreased appetite, alopecia (hair thinning), rash, asthenia (weakness), irritability, myalgia (muscle pain), anemia, pyrexia (fever), cough, dyspnea (shortness of breath), neutropenia, diarrhea, arthralgia (joint pain), thrombocytopenia (low platelet count), and lymphopenia. Most side effects are mild to moderate and manageable. If you take daclatasvir with sofosbuvir and you are also taking amiodarone (a heart rhythm medication), this combination can cause potentially dangerous cardiac side effects. Seek immediate medical attention if you experience dizziness, fainting, or an unusually slow heartbeat.

Drug interaction

Several medications can significantly affect daclatasvir blood levels. Drugs that may cause clinically relevant increases in daclatasvir concentration include: HIV antiviral agents such as atazanavir with ritonavir, indinavir, nelfinavir, and saquinavir; cobicistat-containing antiretroviral regimens (e.g., atazanavir/cobicistat, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate); the anticoagulant dabigatran etexilate mesylate; and strong CYP3A inhibitors such as clarithromycin, itraconazole, ketoconazole, and ritonavir. Conversely, daclatasvir concentrations may be decreased by: NNRTIs including efavirenz, etravirine, and nevirapine; and moderate CYP3A inducers such as bosentan, dexamethasone, modafinil, nafcillin, and rifapentine. Additionally, daclatasvir is an inhibitor of P-glycoprotein transporter (P-gp), organic anion transporting polypeptide (OATP) 1B1 and 1B3, and breast cancer resistance protein (BCRP). Administration of daclatasvir may therefore increase systemic exposure to medications that are substrates of these transporters, potentially intensifying their therapeutic effects or adverse reactions. Always inform your healthcare provider about all medications you are taking.

Missed dose

Take daclatasvir every day at the same regularly scheduled time, with or without food. Consistent daily dosing is essential for maintaining effective antiviral drug levels and achieving sustained virologic response (SVR), which represents a functional cure of hepatitis C. Do not miss or skip doses, and continue taking daclatasvir for the entire duration recommended by your physician. If you do miss a dose and remember within the same day, take it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. For instructions regarding missed doses of sofosbuvir or ribavirin, refer to their respective prescribing information.

Overdose

There is no specific antidote for daclatasvir overdose. Treatment should consist of general supportive measures, including careful monitoring of vital signs, ECG monitoring, and clinical observation of the patient's status. Because daclatasvir is highly protein-bound (greater than 99%), hemodialysis is unlikely to significantly reduce plasma concentrations of the drug. In case of suspected overdose, contact your physician, local poison control center, or emergency medical services immediately.

Storage

Store daclatasvir tablets at 25°C (77°F), with temporary excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from moisture and excessive heat. Keep the medication in its original container with the cap tightly closed. Keep all medications out of the reach of children and pets.

Disclaimer

We provide only general information about medications which does not cover all directions, possible drug integrations, or precautions. Information at the site cannot be used for self-treatment and self-diagnosis. Any specific instructions for a particular patient should be agreed with your health care adviser or doctor in charge of the case. We disclaim reliability of this information and mistakes it could contain. We are not responsible for any direct, indirect, special or other indirect damage as a result of any use of the information on this site and also for consequences of self-treatment.